LABORATORY DIAGNOSIS OF RHEUMATOID ARTHRITIS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The determination of IgM rheumatoid factor (IgM RF) plays a large role in the diagnosis of rheumatoid arthritis (RA). IgM RF-positive patients are predisposed to severe RA. The current markers of the latter include anti-cyclic citrullinated peptide (anti-CCP) antibodies and anti-modified citrullinated vimentin (MCV) antibodies, the sensitivity and specificity of which were higher than IgM RF. RF and anti-CCP and anti-MCV antibodies are markers for predisposition to systemic manifestations and destructive changes in the affected joints and for the efficiency of a chosen treatment policy.

Full Text

Restricted Access

About the authors

N. Shilkina

Yaroslavl State Medical Academy

Email: shilkin39@mail.ru
MD

M. Voronina

Yaroslavl State Medical Academy

Candidate of Medical Sciences

A. Vinogradov

Yaroslavl State Medical Academy

Candidate of Medical Sciences

References

  1. Александрова Е.Н., Новиков А.А., Насонов Е.Л. Клиническое значение антител к циклическому цитруллинированному пептиду: новые данные // Клин. мед. - 2007; 85 (8): 4-9.
  2. Каратеев Д.Е., Александрова Е.Н., Демидова Н.В. и др. Антицитруллиновые антитела и данные магнитно-резонансной томографии суставов кисти у больных ранним артритом // Тер. арх. - 2008; 80 (10): 72-7.
  3. Насонов Е.Л. Фармакотерапия ревматоидного артрита в эру генноинженерных биологических препаратов // Тер. арх. - 2007; 74 (5): 5-8.
  4. Насонова В.А., Фоломеева О.М., Эрдес Ш.Ф. Ревматические заболевания в Российской Федерации в начале XXI века глазами статистики // Тер. арх. -2009; 81 (9): 5-10.
  5. Тогизбаев Г., Новиков А.А., Каратеев Д.Е. Прогностическое значение антител к циклическому цитруллинированному пептиду (АЦЦП) при раннем недифференцированном артрите. // Мат. V съезда ревматологов России. - М., 2009; 112; 429.
  6. Bang H., Egerer K., Gauliard A. et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis // Arthr. Rheum. - 2007; 56 (8): 2503-11.
  7. Bobbio-Pallavicini F., Caporali R., Bugatti S. et al. What can we learn from treatment induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? // J. Rheumatol. - 2008; 35 (10): 1903-6.
  8. Dejaco C., Klotz W., Larcher H. et al. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis // Arthr. Res. Ther. - 2006; 4 (8): 119.
  9. Mathsson L., Mullazehi M., Wick M. et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides // Arthr. Rheum. - 2008; 58 (1): 36-45.
  10. Mutlu N., Bicakcigil M., Tasan D. et al. Comparative performance analysis of different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis // J. Rheumatol. - 2009; 36 (3): 491-500.
  11. Nicaise-Roland P., Grootenboer Mignot S. et al. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy // Arthr. Res. Ther. - 2008; 10 (6): 142.
  12. Quartuccio L., Fabris M., Salvin S. et al. Rheumatoid factor positivity rather then ant-CCP positivity, a lower disability and a lower number anti-TNF agents failed are associated with response to Rituximab in rheumatoid arthritis // Rheumatology. - 2009; 48 (5): 1557-9.
  13. Ronnelid J., Wick M., Lampa J. et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression // Ann. Rheum. Dis. - 2005; 64(12): 1744-9.
  14. Sghiri R., Bouajina E., Bargaoui D. et al. Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis // Rheumatol. Int. - 2008; 29 (1): 59-62.
  15. Soos L., Szekanecz Z., Szabo Z. et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis // J. Rheumatol. - 2007; 34 (8): 1658-63.
  16. Ursum J., Nielen M., van Schaardenburg D. et al. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study // Arthr. Res. Ther. - 2008; 10 (1): 12.
  17. Wagner E., Skoumal M., Bayer P. et al. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis // Rheumatol. Int. - 2009; 29 (1): 1315-21.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies